Transdermal permeation of novel n-acetyl-glucosamine/NSAIDs mutual prodrugs

References

• Albert A. Chemical aspects of selective toxicity. Nature 1958;182(4633):421–423.
   PubMedGoogle Scholar
• Rao H, Surya Prakash. Capping drugs: Development of prodrugs. Accessed February 2003 from the website: Http://www.ias.ac.in/resonance/Feb2003/pdf/Feb2003p19-27.pdf.
   Google Scholar
• Capelli L, Chianese V, La Montagna G, Giordano M. Further studies on glucametacin in rheumatoid arthritis and in other chronic types of rheumatism. Curr Med Res Opinion 1981;7(4):227–233.
   PubMedGoogle Scholar
• Singh G, Sharma PD. Review article: Mutual prodrugs – A recent trend in prodrug design. Indian J Pharm Sci 1994;56(3):69–79.
   Google Scholar
• Ueda I, Tani M. Histamine and its related active substances: Synthesis and pharmacological properties a new chimera drug derived from the combination of anti-inflammatory agent histamine H2 receptor antagonist. Mem Inst Sci Ind Res Osaka Univ 1990;43–54.
   Google Scholar
• Imai T, Fukuhara Ueda I, Otagiri M. An evaluation of an anti-inflammatory-histamine H2 antagonist drug complex on gastric corrosions in the rat. J Pharmacol Exp Ther 1994;265: Exp. 328–333.
   Google Scholar
• Fukuhara A, Imai T, Inoue K, Otagiri M. Effect of oral multiple-dose administration Fukuhara, Imai, Inoue, of anti-inflammatory flurbiprofen chimera drug on gastric lesion, other toxicities and disposition toxicities. Biol Pharm Bull 1995;18:140–147.
   PubMedGoogle Scholar
• Fukuhara A, Imai T, Otagiri M. Stereoselective disposition of flurbiprofen from a Fukuhara, Imai, disposition from mutual prodrug with a histamine H2-antagonist to reduce gastrointestinal lesions in the rat. Chirality 1996;8:494–502.
   PubMedGoogle Scholar
• Otagiri M, Imai T, Fukuhara A. Improving the pharmacokinetic and pharmacodynamic properties of a drug by chemical conversion to a chimer drug. J Con Release 1999;62:223–229.
   PubMed Web of Science ®Google Scholar
• Capomacchia AC, and, US Provisional patent application No. 60/560,128, filed 7 April 2004. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods.
   Google Scholar
• Capomacchia AC, Garner ST. US Patent application 235.00560201, filed 7 April 2005. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods.
   Google Scholar
• Ghodeswar BC, Pophalikar RN, Bhojani MR, Nagpal D, Dhaneshwar SS. Synthesis and pharmacological evaluation of mutual prodrugs of some nonsteroidal antiflammatory drugs with glucosamine. Indian J Pharm Sci 2004;66:773–777.
   Google Scholar
• Bhosale AV, Agrawal GP, Mishra P. Preparation and characterization of mutual prodrugs of ibuprofen. Indian J Pharm Sci 2003;66(2):158–163.
   Google Scholar
• Garner ST, et al. Transdermal permeability of NAG. Pharmaceut Dev Tech 2007;12:169–174.
   PubMed Web of Science ®Google Scholar
• Yuan X, Capomacchia AC. The binary eutectic of NSAIDs and two-phase liquid system for enhanced membrane permeation. Pharmaceut Develop Technol 2005;1:1–10.
   Google Scholar
• Qandil et al. Synthesis of piperazinylalkyl ester prodrugs of ketorolac and their in vitro evaluation for transdermal delivery. Drug Dev Ind Pharm 2008;34:1054–1063.
   PubMed Web of Science ®Google Scholar
• Babazadeh M. Design, synthesis and in vitro evaluation of vinyl ether type polymeric prodrugs of ibuprofen, ketoprofen and naproxen. Int J Pharm 2008;356:167–173.
   PubMedGoogle Scholar
• Silva DJ, et al. J Org Chem 1999;64:5926–5929 (Supplemental material).
   Web of Science ®Google Scholar
• Itoh T, Xia J, Magavi R, Nishihata T, Rytting JH. Use of shed snake skin as a model membrane for in vitro percutaneous penetration studies: Comparison with human skin. Pharm Res 1990;7:1042–1047.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Konishi R. In vitro testing and transdermal delivery. Proceedings of the 2nd Transdermal Therapeutic Symposium. Therapeutic Res 1987;6:280–288.
   Google Scholar
• Ngawhirunpat T, Panomsuk S, Opanasopit P, Rojanarata T, Hatanaka T. Comparison of the percutaneous absorption of hydrophilic and lipophilic compounds in shed snake skin and human skin. Pharmazie 2006;61(4):331–335.
   PubMedGoogle Scholar
• Ngawhirunpat T, Opansopit P, Rojanarata T, Panomsuk S. Evaluation of simultaneous permeation and metabolism of methyl nicotinate in human, snake, and shed snake skin. Pharmaceut Develop Technol 2008; 13:75–83.
   PubMed Web of Science ®Google Scholar
• Franz TJ, Lehman PA, Kagy MK. Dimethyl sulfoxide. In: Smith EW, Maibach HI, editors. Percutaneous enhancers. Boca Raton, FL: CRC Press; 1995:112–127.
   Google Scholar
• Swart H, et al. Synthesis and transdermal penetration of NSAID glycoside esters. Int J Pharm 2005;301:71–79.
   PubMed Web of Science ®Google Scholar
• Bonina FP, Puglia C, Barbuzzi T, Caprariis PD, Rimoli MG. In vitro and in vivo evaluation of polyoxyethenene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci 2001;14:123–134.
   PubMed Web of Science ®Google Scholar
• Doh H-J Cho, WJ, Yong CS, Choi HG, Kim JS, Lee CH. Synthesis and evaluation of ketorolac ester prodrugs for transdermal delivery. J Pharm Sci 2003;92:1008–1017.
   PubMedGoogle Scholar
• Kim B-Y, et al. Ketorolac amide prodrugs for transdermal delivery: Stability and in vivo transdermal stability rat skin permeation studies. Int J Pharm 2004;293:193–202.
   Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23(1–3):3–25.
   Web of Science ®Google Scholar
• The Merck Index. 12th ed. Whitehouse Station, NJ: Merck & Co, 1996; pp 758, 839, 905.
   Google Scholar
• D’Souza AJM, Topp EM. Release from polymeric prodrugs: Linkages and their degradation. J Pharm Sci 2004;93(8):1962–1979.
   PubMedGoogle Scholar
• McClain DA, Crook ED. Hexosamines and insulin resistance. Diabetes 1996;45:1003–1009.
   PubMed Web of Science ®Google Scholar
• Singh LP, Andy J, Anyamale V, Greene K, Alexander M, Crook ED. Hexosamine-induced fibronectin protein synthesis in mesangial cells is associated with increases in cAMP responsive element binding (CREB) phosphorylation and nuclear CREB: The involvement of protein kinases A and C. Diabetes 2001;50:2355–2362.
   PubMed Web of Science ®Google Scholar
• Miwa I, Mita Y, Murata T, Okuda J, Sugiura M, Hamada Y, Chiba T. Utility of 3-O-methyl-N-acetyl-D-glucosamine, an N-acetylglucosamine kinase inhibitor, for accurate assay of glucokinase in pancreatic islets and liver. Enzyme Protein 1994;48:135–142.
   PubMedGoogle Scholar
• Van Schaftigen E. Glucosamine-sensitive and -insensitive detritiation of [2-3H] glucose in isolated rat hepatocytes: A study of the contributions of glucokinase and glucose-6- phosphatase. Biochem J 1995;308:23–29.
   PubMedGoogle Scholar
• Virkamaki A, Yki-Jarvinen H. Allosteric regulation of glycogen synthase and hexokinase by glucosamine-6-phosphate during glucosamine-induced insulin resistance in skeletal muscle and heart. Diabetes 1999;48:1101–1107.
   PubMedGoogle Scholar
• Gouze JN, Bianchi A, Becuwe P, Dauca M, Netter P, Magdalou J, Terlain B, Bordji K. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level and by inhibiting the NF-B pathway. FEBS Lett 2002;510:166–170.
   PubMed Web of Science ®Google Scholar
• Poustie MW, Carran J, McEleney K, Dixon SJ, Anastassiades TP, Bernier SMJ. N-butyryl glucosamine increases matrix gene expression by chondrocytes. Pharmacol Exp Ther 2004;311(2):610–616.
   PubMedGoogle Scholar
• Anastassiades TP. Treatment of arthritis and compositions therefore. 2001. United States Patent Application No. 20020045597.
   Google Scholar
• Anastassiades TP. Methods and compositions using N-acyl 2-glucosamine derivatives for the treatment of arthritis. 2002. PCT Int. Appl. WO 2002017890 A2 20020307 CAN 136:210563 AN 2002:171660.
   Google Scholar
• Anastassiades TP. Amelioration of decreased weight and growth by N-acylated glucosamines. 2003. United States Patent Application No. 20040152665.
   Google Scholar
• Setnikar I, Giacchetti C, Zanolo G. Pharmacokinetics of glucosamine in the dog and in man. Arzneimittel-Forschung 1986;36(4):729–735.
   PubMedGoogle Scholar
• Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneimittel-Forschung 1993;43(10):1109–1113.
   PubMedGoogle Scholar
• Setnikar I, Rovati LC. Absorption, distribution, metabolism,and excretion of glucosamine sulfate. A review. Arzneimittel-Forschung 2001;51(9):699–725.
   PubMedGoogle Scholar
• Setnikar et al. The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharmaceut Drug Disposit 2004;25(3):109–116.
   PubMedGoogle Scholar
• Du J, White N, Eddington ND. The bioavailability and pharmacokinetics of pharmacokinetics glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharmaceut Drug Disposit 2004;25(3):109–116.
   PubMedGoogle Scholar
• Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharmaceut Sci 2000;5(2):181–184.
   Google Scholar